NCF1 and non-small cell lung carcinoma: A longer progression free survival (PFS) of patients with primary non-small cell lung cancer (NSCLC) was associated with higher levels of Ncf1, and low levels of Ncf1 may be used as a biomarker for predicting response of patients with primary NSCLC to anti-PD-1 therapy (16).